'Transformation growth': Polynovo share price jumps 7% on new leadership

Polynovo just appointed its new CEO…

| More on:
Three scientists wearing white coats and blue gloves dance together in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares make are making another strong comeback today, rising more than 7% after significant falls earlier in the week
  • The company appointment its new CEO, Swami Raote, with immediate effect
  • Raote spent a 30-year career at Johnson & Johnson where he was pivotal in transforming the business

The Polynovo Ltd (ASX: PNV) share price is surging on Friday afternoon.

This comes after the medical device company's shares tumbled almost 20% this week before staging a mini-comeback yesterday.

At the time of writing, the medical device company's shares are swapping hands at $1.62, up 7.29% – slightly under last Friday's close of $1.725.

Let's look at what the company announced to the market today.

Polynovo bolsters leadership team

Investors are snapping up Polynovo shares after the company revealed it had secured the services of an experienced pharmaceutical leader.

In today's release, Polynovo advised Swami Raote has been appointed as company CEO with immediate effect.

This sees acting CEO Max Johnston exit the role after serving since November 2021.

Polynovo noted Raote's achievements, particularly his 30-year career at global pharmaceutical giant Johnson & Johnson.

During his time there, Raote earned a reputation as a transformation growth leader across fast-moving consumer goods, over-the-counter products, pharmaceuticals, and medical devices.

He also held senior leadership positions at Johnson & Johnson across various geographies of interest to Polynovo. This includes Indonesia, the Association of Southeast Asian Nations (ASEAN), India, China, South Korea, and the United States.

Raote is currently "an advisor to the prime minister of a major Asian country that is building a digital health platform", according to his biography.

Furthermore, he's in several other advisory roles, which Polynovo will review to consider potential market opportunities.

Management commentary

Polynovo chair David Williams welcomed the news, saying:

Swami has successfully run fully integrated businesses including research and development, regulatory, manufacturing, and sales and marketing. That experience along with hands on experience in many geographies and markets will position Polynovo for an exciting new era of growth, innovation, and operational excellence.

On a lighter note, Williams added:

Swami is 58 years old and given he is significantly younger than me, I judge he has more than enough energy for the challenge.

Polynovo share price snapshot

Despite its recent gains, the Polynovo share price has plummeted 30% over the last 12 months.

The company's shares hit a 52-week low of 83.5 cents on 5 May and have been treading upwards since.

Based on today's price, Polynovo commands a market capitalisation of more than $1 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »